SHR-A2102: Clinical Trials

12 trials of SHR-A2102, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting, 1 not yet recruiting, 1 unknown. 12 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Recruiting 10, Not yet recruiting 1, Unknown 1
Phase 14Recruiting 3, Unknown 1
Phase 31Recruiting 1

Follow SHR-A2102: new trials by email Literature Review of SHR-A2102 trials Research Report on SHR-A2102

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
SHR-A2102, Adebrelimab, Paclitaxel - Non-small Cell Lung Cancer
Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.3002025-11-242025-12-01
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
SHR-A2102, Adebrelimab, Cetuximab - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2102025-07-112026-07-20
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
SHR-A2102, Adebrelimab - Advanced Breast Cancer
Phase 2Not yet recruitingFudan University482025-06-302025-06-27
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
SHR-A2102, Adebrelimab, Gemcitabine Hydrochloride for Injection - Muscular Invasive Bladder Cancer (MIBC)
Phase 2 / Phase 3RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.7402025-04-252026-11-12
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
SHR-A2102, Bevacizumab Injection, Adebelimab Injection - Advanced Solid Tumors
Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.4002025-03-282025-04-22
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
SHR-A2102, Adebrelimab injection, SHR-8068 injection - Advanced Urothelial Carcinoma
Phase 1 / Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.902024-11-042024-11-18
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer
Phase 2RecruitingFudan University1602024-10-212026-09-03
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
SHR-A2102, Adebelimab (SHR-1316), SHR-8068 - Non-Small Cell Lung Cancer
Phase 1 / Phase 2UnknownShanghai Hengrui Pharmaceutical Co., Ltd.1242024-09-272024-11-12
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
SHR-A1811, SHR-A1921, Adebrelimab - Advanced Breast Cancer
Phase 2RecruitingBeijing GoBroad Hospital1132024-08-052026-07-14
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
SHR-A2102, SHR-A2102 ; Adebrelimab injection, SHR-A2102 + Disitamab Vedotin For Injection - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.802024-05-272026-08-24
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer
Phase 2RecruitingFudan University6202022-12-302024-10-04
Reverse Triple Negative Immune Resistant Breast Cancer
Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate - Triple-negative Breast Cancer
Phase 2RecruitingFudan University902022-06-302026-10-23

Conditions studied

Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd. (5)  ·  Fudan University (4)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2)  ·  Beijing GoBroad Hospital (1)

Countries

China (12)

Top investigators

Hongxia Wang, Chief physician (1)  ·  Wei Zhao (1)  ·  Xichun Hu, Chief physician (1)  ·  Zhimin Shao, M.D. (1)  ·  Zhimin Shao, Professor (1)

Results publications

PMID 40563015